Potential boost to U.S. GDP from GLP-1 medications 

Upside to GDP, by number of users and effectiveness scenario

Low = 50% of users benefit from labor supply/productivity effects, which are at 25th percentile of academic estimates. Middle = 70% of users benefit at 50th percentile. High = 90% of users benefit at 75th percentile.
THE GLOBE AND MAIL Source: Goldman Sachs